ATS 2024 Final Program

Click on the session title to view the speakers

134

MONDAY • MAY 20

921 Checkpoint Inhibitor Pathway Dysfunction in Pulmonary Fibrosis 922 Perinatal Obesity Induces Premature Alveolar Aging by AT2 Cell Depletion Via IL-6-driven Transcriptional Stress and Genome Instability 923 p16 INK4a + Fibroblasts Regulate Epithelial Regeneration After Injury in Lung Alveoli Through the SASP 924 Impaired Fatty Acid Oxidation Influences Nuclear Dynamics in Alveolar Type 2 Epithelial Cells

707 Machine Learning Analysis of Serial Electronic Health Record Data Identifies Clinical Biomarkers of Progressive Lung Function Impairment in Patients With Scleroderma 708 Staying in the Flow: Preferential PDE4B Inhibitor Nerandomilast (BI 1015550) Improves Features of Vascular Dysfunction in Lung Fibrosis In Vitro and In Vivo 709 PEG-FUD, A Promising Probe for Pulmonary Fibrosis, Targets the Pro-fibrotic Phase of Disease 710 Therapeutic Targeting of Aberrant Transitional Epithelial Cells in Lung Fibrosis Through NOX4 Inhibition 711 MZB1+ Plasma Cells as Potential Therapeutic Targets for Cell Depletion in Interstitial Lung Diseases 712 GTX-11 Alleviates Fibrosis, Inflammation, and Cardiovascular Dysfunction in Different Models of Lung Fibrotic Disease 713 A First-in-Human Clinical Trial of Pulmonary Macrophage Transplantation Therapy of Hereditary Pulmonary Alveolar Proteinosis Caused by Biallelic CSF2RA Mutations 714 Variations in S100A8/A12 Gene Expression Are Associated With the Efficacy of Nintedanib and Acute Exacerbation Development in IPF Patients 715 Targeting a Novel TRPV4-PI3Kg Interaction Blocks Fibrogenic Myofibroblast Differentiation 716 Synergistic Effects of Nintedanib With BCL-2 Inhibition to Drive Pro-fibrotic Fibroblast Apoptosis 717 P53 and miR-34A Feedback Regulates Antifibrotic Effects of CSP7, Nintedanib and Pirfenidone in Lung Fibroblasts 718 Bexotegrast Targets TGF-beta Inhibition to Specific Cell Types in the Fibrotic Human Lung 719 Preclinical Data Supports Assessment of Target Engagement in Skin as a Surrogate for Lung in Clinical Trials of the Porcupine Inhibitor AZD5055 Reprogramming and Its Potential as a Therapeutic Target for Pulmonary Fibrosis 721 LAPTM4B Modulates the TGFß-SMAD Signaling by Interacting With E3 Ubiquitin Ligase NEDD4L in IPF 720 Upregulation of MARCKS in Macrophage

BASIC • TRANSLATIONAL POSTER DISCUSSION SESSION

B29 BIOMARKERS AND NEW

THERAPEUTICS TARGETS IN LUNG FIBROSIS

9:15 a.m. - 11:15 a.m.

San Diego Convention Center Room 30C-E (Upper Level)

Poster Viewing

9:15-10:00

Discussion 10:00-11:15 701 Combination of IFN- g With Ferroptosis Inducers Effectively Attenuates Bleomycin-induced Pulmonary Fibrosis in Mice 702 Nebulizable Conjugates to Sustain Retention, Delivery, and Efficacy of Galectin-3 Inhibitory Drug TD139 in the Alveolar Space 703 The Role of Erythrocyte Membrane Protein Band 4.1-like 3 as a Prognostic Biomarker in Idiopathic Pulmonary Fibrosis 704 Composite Fibrosis Scoring From Serum Biomarkers for Early Detection of Progressive Hermanky-Pudlak Syndrome Pulmonary Fibrosis 705 Latent Class Analysis of Two Observational Cohorts Identifies Two Biomarker-derived Subtypes of Fibrotic Interstitial Lung Disease (ILD) With Differential Mortality 706 Targeting mGluR5 in Fibroblasts Provides a Promising Avenue in Idiopathic Pulmonary Fibrosis: Prospective of Repositioning Basimglurant, A Negative Allosteric Modulator of mGluR5

ATS 2024 Conference Program • San Diego, CA